Nohla raises $43.5M series A round

Nohla Therapeutics Inc. (Seattle, Wash.) raised $43.5 million in a series A round led by new investor Arch Venture Partners. New investor 5AM Ventures and existing investor Jagen Group also participated.

Nohla’s lead programs, NLA-101 and NLA-102, are off-the-shelf, allogeneic ex vivo cord blood transplant products that do not require human leukocyte antigen (HLA) matching. Interim CEO Michael Sistenich said the products are designed to avoid the side effects and problems associated with stem cell transplants and are meant to be used as bridging products to support engraftment. In pilot studies, Sistenich said Nohla’s product “substantially" reduced treatment-related mortality, infections and graft-versus-host disease (GvHD). ...